N-[(4-氧代环己基)甲基]乙酰胺 | 30482-18-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[(4-氧代环己基)甲基]乙酰胺
• 中文别名: N-（4-氧代-环己基甲基）-乙酰胺
• 英文名称: N-[(4-oxocyclohexyl)methyl]acetamide
• 英文别名: N-(4-Oxo-cyclohexylmethyl)-acetamide
• CAS: 30482-18-9
• 化学式: C₉H₁₅NO₂
• mdl: MFCD11040609
• 分子量: 169.224
• InChiKey: QAXXVSNCADPNGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[(4-氧代环己基)甲基]乙酰胺 在 氢氧化钾 、 三乙胺 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 10.0h， 生成 (+/-)-N-[(2-acetyl-4,5,6,7-tetrahydro-2H-izoindol-5-yl)methyl]acetamide
  参考文献：
  名称：

  A general synthetic approach to novel conformationally restricted arginine side chain mimetics

  摘要：

  A general synthesis of several novel partially saturated, conformationally restricted heterobicyclic arginine side chain mimetics is described. These compounds are interesting peptidomimetic building blocks for incorporation into trypsin-like serine protease inhibitors. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)01243-1
• 作为产物：
  描述：

  4-氰基环己酮缩乙二醇 在 lithium aluminium tetrahydride 、 甲酸 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 生成 N-[(4-氧代环己基)甲基]乙酰胺
  参考文献：
  名称：

  A general synthesis of novel conformationally restricted arginine side-chain mimetics

  摘要：

  6-(Aminomethyl)-5,6,7,8-tetrahydro-2-quinazolinamine and 4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine were synthesized as novel conformationally restricted arginine side-chain mimetics, designed for incorporation into trypsin-like serine protease inhibitors. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)00869-8

文献信息

• [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011159854A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括公式(I)的化合物。其中：R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。
• MASP-2 INHIBITORS AND METHODS OF USE
  申请人：Omeros Corporation

  公开号：US20190367452A1

  公开（公告）日：2019-12-05

  The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

  本公开提供了具有MASP-2抑制活性的化合物，这些化合物的组合物以及制造和使用这些化合物的方法。
• Thrombin inhibitors
  申请人：——

  公开号：US20030191139A1

  公开（公告）日：2003-10-09

  The invention relates to compounds of formula I D—CO—B—A-Het and pharmaceutically acceptable salts thereof where substituents in description have the specified meanings. The compounds are used as thrombin inhibitors.

  该发明涉及公式I的化合物D—CO—B—A-Het及其药用可接受的盐，其中描述中的取代基具有指定的含义。这些化合物被用作凝血酶抑制剂。
• Novel non-covalent thrombin inhibitors incorporating P1 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics
  作者：Petra Marinko、Aleš Krbavčič、Gregor Mlinšek、Tomaž Šolmajer、Alenka Trampuš Bakija、Mojca Stegnar、Jure Stojan、Danijel Kikelj

  DOI：10.1016/j.ejmech.2003.12.006

  日期：2004.3

  The design, synthesis and biological activity of a series of novel non-covalent D-Phe-Pro-Arg motif-based thrombin inhibitors incorporating 4,5,6,7-tetrahydrobenzothiazol-2-amine as a novel arginine surrogate are described. Compound 9, the most potent in the series of thrombin inhibitors, exhibited an in vitro K(i) of 128 nM and 342-fold selectivity against trypsin. The binding mode of this novel class

  描述了一系列新型的基于非共价D-Phe-Pro-Arg主题的凝血酶抑制剂的设计，合成和生物学活性，该抑制剂结合了4,5,6,7-四氢苯并噻唑-2-胺作为新型的精氨酸替代物。一系列凝血酶抑制剂中最有效的化合物9的体外K（i）为128 nM，对胰蛋白酶的选择性为342倍。基于与人α-凝血酶共结晶的化合物9的X射线晶体结构，讨论了这类新型凝血酶抑制剂在酶活性位点的结合方式。
• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Lanter James C.

  公开号：US20110312936A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 4 , J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明涉及I式化合物，其中：R1、R2、R4、J、Q和A如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。本发明还涉及通过给哺乳动物施加至少一种I式化合物的治疗有效量来抑制CCR2活性的方法。